NovelStem International Past Earnings Performance
Past criteria checks 0/6
NovelStem International's earnings have been declining at an average annual rate of -40.2%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 71.5% per year.
Key information
-40.2%
Earnings growth rate
-38.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 71.5% |
| Return on equity | n/a |
| Net Margin | -25,144.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How NovelStem International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -3 | 1 | 0 |
| 30 Jun 24 | 0 | -2 | 0 | 0 |
| 31 Mar 24 | 0 | -4 | 1 | 0 |
| 31 Dec 23 | 0 | -4 | 1 | 0 |
| 30 Sep 23 | 0 | -4 | 1 | 0 |
| 30 Jun 23 | 0 | -4 | 1 | 0 |
| 31 Mar 23 | 0 | -1 | 1 | 0 |
| 31 Dec 22 | 0 | -1 | 1 | 0 |
| 30 Sep 22 | 0 | -1 | 1 | 0 |
| 30 Jun 22 | 0 | -1 | 1 | 0 |
| 31 Mar 22 | 0 | -1 | 1 | 0 |
| 31 Dec 21 | 0 | -1 | 0 | 0 |
| 31 Dec 20 | 0 | -1 | 0 | 0 |
| 31 Dec 13 | 0 | 6 | 3 | 0 |
Quality Earnings: NSTM is currently unprofitable.
Growing Profit Margin: NSTM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NSTM is unprofitable, and losses have increased over the past 5 years at a rate of 40.2% per year.
Accelerating Growth: Unable to compare NSTM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NSTM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: NSTM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.